Maas, Jens-Holger

[["dc.bibliographiccitation.firstpage","1127"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1133"],["dc.bibliographiccitation.volume","96"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:22:22Z"],["dc.date.available","2018-11-07T10:22:22Z"],["dc.date.issued","2017"],["dc.description.abstract","Graft-versus-host disease (GvHD) still belongs to the major challenges after allogeneic hematopoietic stem cell transplantation (HSCT). Immune-suppressive therapy against GvHD is a double-edged sword due to risk of infections and relapse. The ability to adapt prophylactic treatment according to the probability of severe GvHD would be an essential advantage for the patients. We analyzed different biomarkers for their potential to predict the development of GvHD in 28 patients who underwent allogeneic HSCT. Blood was taken once directly after hematopoietic engraftment. In this study, patients were monitored for 12 months after HSCT for the occurrence of acute GvHD or acute/chronic GvHD overlap syndrome. Soluble IL-2 receptor and CD4/CD8 T cell ratio were independently associated with the occurrence of GvHD in the observation period. However, the largest area under the receiver operating characteristic curve with 0.90 was observed when a 5-parameter biomarker score based on CD4(+) T cells, CD8(+) T cells, CD19(-) CD21(+) precursor B cells, CD4/CD8 T cell ratio, and soluble IL-2 receptor was used to predict GvHD. In addition, CD8(+) T cell levels above 2.3% of all mononuclear cells after engraftment may predict relapse-free survival at least for 12 months. In summary, we found a new biomarker panel for prediction of GvHD which is featured by established laboratory assays and high statistical significance. In order to introduce the biomarker panel into routine clinical protocols, we suggest performing a larger multi-center study."],["dc.identifier.doi","10.1007/s00277-017-2999-5"],["dc.identifier.isi","000403078900008"],["dc.identifier.pmid","28447161"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42255"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1432-0584"],["dc.relation.issn","0939-5555"],["dc.title","Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","HLA"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:23:29Z"],["dc.date.available","2018-11-07T10:23:29Z"],["dc.date.issued","2017"],["dc.format.extent","362"],["dc.identifier.isi","000400973300051"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42466"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley"],["dc.publisher.place","Hoboken"],["dc.relation.issn","2059-2310"],["dc.relation.issn","2059-2302"],["dc.title","SCREENING FOR A BIOMARKER PANEL FOR PREDICTION OF GRAFT VERSUS HOST DISEASE IN HUMANS"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","327"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Leukemia Research"],["dc.bibliographiccitation.lastpage","332"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Hartmann, Julia"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Sinzig, Ursula"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Maas, Jens Holger"],["dc.contributor.author","Konietschke, Frank"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T09:27:53Z"],["dc.date.available","2018-11-07T09:27:53Z"],["dc.date.issued","2013"],["dc.description.abstract","In patients with myelodysplastic syndromes (MDS) iron overload caused by long-term red blood cell transfusions is an important factor for comorbidity especially in low-risk MDS. In this report we present the results of a comparative study based on colony formation assays of hematopoietic cells in MDS patients with and without iron overload. We demonstrate that iron overload suppresses the proliferation of erythroid progenitors cells (BFU-E), while the myeloid compartment (CFU-GM) was not found to be affected. Even patients with slightly elevated ferritin values show an impaired proliferation capacity in comparison to patients with normal ferritin levels. Furthermore, we show that this negative impact is reversible by sufficient iron chelation therapy. (C) 2012 Elsevier Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.leukres.2012.11.005"],["dc.identifier.isi","000314871500018"],["dc.identifier.pmid","23259989"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11341"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30643"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.relation.issn","0145-2126"],["dc.rights","CC BY-NC-ND 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/3.0"],["dc.title","Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1033"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Transfusion"],["dc.bibliographiccitation.lastpage","1041"],["dc.bibliographiccitation.volume","47"],["dc.contributor.author","Humpe, Andreas"],["dc.contributor.author","Jansen, Pal"],["dc.contributor.author","Tischer, Bernd Karsten"],["dc.contributor.author","Schubert, Sabine"],["dc.contributor.author","Beck, Christian"],["dc.contributor.author","Adamzik, Ilse-Dorothea"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Strate, Alexander"],["dc.contributor.author","Gramatzki, Martin"],["dc.contributor.author","Riggert, Joachim"],["dc.date.accessioned","2018-11-07T11:02:17Z"],["dc.date.available","2018-11-07T11:02:17Z"],["dc.date.issued","2007"],["dc.description.abstract","Background: Manipulations, for example, cryopreservation, of cellular therapeutics carried out in an open system must be performed in a class A environment with surrounding class B environment. To avoid cleanroom facilities, a new closed-bag system with an incorporated dimethyl sulfoxide-resistant sterile filter for cryopreservation of cellular products was evaluated at two different centers. Study Design and Methods: A total of 44 different products (22 buffy coats [BCs] and 22 leukapheresis [LK] products) were split and cryopreserved in parallel in cleanroom facilities (Method I) and with the closed system on the bench of a \"normal\" laboratory (Method II). Viability analyzed by 7-aminoactinomycin D staining and flow cytometric analysis and sterility of the products were analyzed. Results: Independent of the cellular source (BC or LK), the median viability of CD45+ cells decreased significantly (p < 0.01) during cryopreservation: namely, in BCs, -15.8 percent with both methods, and in LK products, -5.4 percent with Method I and -4.8 percent with Method II, respectively. CD3+ as well as CD14+ cells exhibited a similar pattern and were also found significantly (p < 0.01) diminished after thawing independent of the handling system. For CD19+ cells, the small decrease of viability was only for the BC group significant (p = 0.027) when the cells had been processed with Method I. No bacterial contamination was detected neither in fresh products nor in products after cryopreservation. Conclusion: The closed system for cryopreservation of cellular products appears to be equivalent to cleanroom-based methods regarding cellular integrity and sterility when appropriate quality of sterile filters is assured."],["dc.identifier.doi","10.1111/j.1537-2995.2007.01232.x"],["dc.identifier.isi","000246714500014"],["dc.identifier.pmid","17524094"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51347"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing"],["dc.relation.issn","0041-1132"],["dc.title","Cryopreservation of cellular products in a closed-bag system with an incorporated dimethyl sulfoxide-resistant sterile filter outside of cleanroom facilities"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3051"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Journal of Clinical Medicine"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Lipphardt, Mark"],["dc.contributor.author","Dihazi, Hassan"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Schäfer, Ann-Kathrin"],["dc.contributor.author","Amlaz, Saskia I."],["dc.contributor.author","Ratliff, Brian B."],["dc.contributor.author","Koziolek, Michael J."],["dc.contributor.author","Wallbach, Manuel"],["dc.date.accessioned","2021-04-14T08:32:33Z"],["dc.date.available","2021-04-14T08:32:33Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.3390/jcm9093051"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17590"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83944"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","MDPI"],["dc.relation.eissn","2077-0383"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","350"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Cytotherapy"],["dc.bibliographiccitation.lastpage","358"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Dettke, Markus"],["dc.contributor.author","Buchta, Christoph"],["dc.contributor.author","Wiesinger, Helfried"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Strate, Alexander"],["dc.contributor.author","Chen, Ying"],["dc.date.accessioned","2018-11-07T09:15:38Z"],["dc.date.available","2018-11-07T09:15:38Z"],["dc.date.issued","2012"],["dc.description.abstract","Background aims. Little is known of the effect of anticoagulation on peripheral blood progenitor cell (PBPC) harvest during large-volume leukapheresis (LVL). Because of the interaction of heparin with stromal cell-derived factor (SDF)-1 alpha, it has been proposed that a heparin-based anticoagulation may result in an increased PBPC collection efficiency compared with standard citrate-based anticoagulation. Methods. We conducted a prospective randomized trial to address the effect of both anticoagulation regimes on safety, subjective comfort and CD34(+) collection efficiency in 90 adult patients undergoing standardized LVL. Anticoagulation consisted of either citrate (group C) or a combination of heparin and low-dose citrate (group H). Results. The overall incidence of adverse reactions (AR) during LVL was 17%. AR consisted only of citrate-related AR; no bleeding complications were observed. Determination of parameters of the acid-base balance revealed a higher frequency of metabolic alkalosis in group C. Analysis of serum SDF-1 alpha revealed no differences in SDF-1 alpha plasma levels. There were no differences in the CD34 cell collection efficiency, resulting in the harvest of equal CD34(+) cell yields independent of the anticoagulation used. Conclusions. Our data show no clinical relevant effect of a heparin containing anticoagulation in terms of an increased overall CD34(+) cell collection during LVL,, although this regime shows some benefits in terms of the incidence and subjective tolerance towards AR. Based on our results the decision between a citrate- and heparin-substituted anticoagulation for LVL should be driven by patient-related factors, and should concern potential contraindications of both methods."],["dc.identifier.doi","10.3109/14653249.2011.635643"],["dc.identifier.isi","000300966100011"],["dc.identifier.pmid","22132997"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27741"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Informa Healthcare"],["dc.relation.issn","1465-3249"],["dc.title","Anticoagulation in large-volume leukapheresis: comparison between citrate- versus heparin-based anticoagulation on safety and CD34(+) cell collection efficiency"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","383"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Transfusion Medicine"],["dc.bibliographiccitation.lastpage","388"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Maas, J. H."],["dc.contributor.author","Kohler, M."],["dc.contributor.author","Wagner, T."],["dc.contributor.author","Daniels, G. L."],["dc.contributor.author","Perco, P."],["dc.contributor.author","Panzer, S."],["dc.date.accessioned","2018-11-07T08:38:07Z"],["dc.date.available","2018-11-07T08:38:07Z"],["dc.date.issued","2001"],["dc.description.abstract","The serological differentiation of weak D from partial D, D-negative and D-positive is not always unequivocal. Therefore, sequencing of the RHD gene is required in some cases. Very recently, several new differences between RHD and RHCE have been identified which permitted us to design primers close to the exon/intron boundaries of the RHD-exons. We evaluated these primers in 83 D-positive and 18 D-negative blood donors and applied the new method for the characterization of the RHD gene in six individuals with weak D phenotype. The amplification reactions were concordant with serological findings in 100 of 101 donors (99.0%). In one D-positive donor the PCR for exons 2 and 5 gave a negative result, while the sequence of the remaining eight exons was unchanged. By sequencing samples with very weak D serological reactions, we identified weak D type 4.2.2 and weak D type 15, both previously reported to be associated with anti-D-alloimmunization. Consequently, we recommended the selection of D-negative blood in the weak D type 4.2.2 patient, and the provision of Rh prophylaxis for pregnant women with weak D type 15. In summary, a new RHD sequencing method was developed which can be applied if serological reactions are inconclusive."],["dc.identifier.doi","10.1046/j.1365-3148.2001.00327.x"],["dc.identifier.isi","000171923400005"],["dc.identifier.pmid","11696232"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18694"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Science Ltd"],["dc.relation.issn","0958-7578"],["dc.title","RHD sequencing: a new tool for decision making on transfusion therapy and provision of Rh prophylaxis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","263"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Vox Sanguinis"],["dc.bibliographiccitation.lastpage","265"],["dc.bibliographiccitation.volume","86"],["dc.contributor.author","Schanz, J."],["dc.contributor.author","Wolf, C."],["dc.contributor.author","Koehler, M."],["dc.contributor.author","Maas, J. H."],["dc.contributor.author","Meyer, M."],["dc.contributor.author","Neumeyer, H."],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Riggert, Joachim"],["dc.date.accessioned","2018-11-07T10:49:32Z"],["dc.date.available","2018-11-07T10:49:32Z"],["dc.date.issued","2004"],["dc.identifier.doi","10.1111/j.0042-9007.2004.00486.x"],["dc.identifier.isi","000221402500007"],["dc.identifier.pmid","15144532"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48455"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing Ltd"],["dc.relation.issn","0042-9007"],["dc.title","Rhabdomyolysis in allogeneic peripheral blood stem cell donors"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","PII S1473-0502(02)00068-X"],["dc.bibliographiccitation.firstpage","217"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Transfusion and Apheresis Science"],["dc.bibliographiccitation.lastpage","223"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Lynen, Rainer"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Pindur, Gerhard"],["dc.contributor.author","Kulenkampff, Dietrich"],["dc.contributor.author","Suren, Anette"],["dc.contributor.author","Osmers, Rüdiger"],["dc.contributor.author","Köhler, Michael"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2021-06-01T10:50:22Z"],["dc.date.available","2021-06-01T10:50:22Z"],["dc.date.issued","2002"],["dc.description.abstract","Real-time PCR methods for the detection of RHD and the C, c, and E allele of RHCE were applied for the prediction of fetal Rh phenotype using maternal plasma. In one of 36 samples investigated the DNA extraction failed. When we tested the remaining 35 samples for Rh antigens which were absent on the mother's red cells, the fetal D-status was correctly determined in 26 of 27 cases (1 false negative). Fetal C was tested correctly in 23 samples, c was true positive in the only c-negative woman and the fetal E-status was correctly determined in 35 cases. In conclusion real-time PCR of maternal plasma is a non-invasive method to determine fetal RH genotype. However, more studies are required for routine applications because the method is not 100% sensitive. (C) 2002 Elsevier Science Ltd. All rights reserved."],["dc.identifier.doi","10.1016/S1473-0502(02)00068-X"],["dc.identifier.isi","000179790300006"],["dc.identifier.pmid","12509216"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86635"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.relation.issn","1473-0502"],["dc.title","Prediction of fetal Rh D and Rh CcEe phenotype from maternal plasma with real-time polymerase chain reaction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Bone Marrow Transplantation"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Humpe, Andreas"],["dc.contributor.author","Jansen, P."],["dc.contributor.author","Beck, C."],["dc.contributor.author","Adamzik, I."],["dc.contributor.author","Maas, J."],["dc.contributor.author","Gramatzki, Martin"],["dc.contributor.author","Riggert, Joachim"],["dc.date.accessioned","2018-11-07T10:10:06Z"],["dc.date.available","2018-11-07T10:10:06Z"],["dc.date.issued","2006"],["dc.format.extent","S65"],["dc.identifier.isi","000236520200160"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39791"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.publisher.place","London"],["dc.relation.conference","32nd Annual Meeting of the European-Group-for-Blood-and-Morrow-Transplantation/22nd Meeting of the EBMT-Nures-Group/5th Meeting of the EMBT-Data-Management-Group"],["dc.relation.eventlocation","Hamburg, GERMANY"],["dc.relation.issn","0268-3369"],["dc.title","Cryopreservation of cellular products in a closed bag system with an incorporated dimethyl-sulfoxide-resistant sterile filter outside of cleanroom facilities"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]